---
document_datetime: 2025-12-02 05:53:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/oxlumo.html
document_name: oxlumo.html
version: success
processing_time: 0.0935343
conversion_datetime: 2025-12-27 21:10:01.272107
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Oxlumo

[RSS](/en/individual-human-medicine.xml/67383)

##### Authorised

This medicine is authorised for use in the European Union

lumasiran Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Oxlumo](#news-on)
- [More information on Oxlumo](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Oxlumo is a medicine used for treating primary hyperoxaluria type 1, an inherited disease in which a substance called oxalate builds up in the body, causing damage to the kidneys and other organs.

Oxlumo contains the active substance lumasiran.

Primary hyperoxaluria is rare, and Oxlumo was designated an 'orphan medicine' (a medicine used in rare diseases) on 21 March 2016.

Expand section

Collapse section

## How is Oxlumo used?

Oxlumo can only be obtained with a prescription and treatment should be started and supervised by a physician experienced in the management of hyperoxaluria.

Oxlumo is given by injection under the skin. It is given once a month for the first 3 months and then either once monthly or once every 3 months. The dose and frequency depend on the patient's weight.

For more information about using Oxlumo, see the package leaflet or contact your doctor or pharmacist.

## How does Oxlumo work?

Patients with primary hyperoxaluria type 1 have high levels of glyoxylate which is converted into oxalate. High levels of oxalate can cause stones in the kidney as well as injury to certain organs.

The active substance in Oxlumo, lumasiran, blocks the production of an enzyme called hydroxyacid oxidase (also known as glycolate oxidase), which is involved in the production of glyoxylate. Oxlumo is a 'small interfering RNA' (siRNA), a very short piece of synthetic genetic material, which has been designed to attach and block the genetic material in the cell that is responsible for the production of the enzyme. This blocks the production of the enzyme, thereby reducing the amount of glyoxylate and oxalate, helping to relieve the symptoms of the disease.

## What benefits of Oxlumo have been shown in studies?

Oxlumo has been shown to reduce the formation of oxalate compared to placebo (a dummy treatment) in a main study with 39 patients aged between 6 and 60 years with primary hyperoxaluria type 1.

After 6 months of treatment, the level of oxalate in urine was reduced by 65% on average in patients on Oxlumo compared with 12% in patients from 6 years of age who received placebo. Among the patients who received Oxlumo, 21 out of 25 (84%) achieved normal or near normal levels of oxalate after 6 months, compared to none in the placebo group. Similar effects were seen in a study with 18 children aged under 6 years with hyperoxaluria type 1.

## What are the risks associated with Oxlumo?

The most common side effects with Oxlumo (which may affect more than 1 in 10 people) are reactions at the injection site such as reddening of the skin, pain, itching and swelling.

For the full list of side effects and restrictions of Oxlumo, see the package leaflet.

## Why is Oxlumo authorised in the EU?

Oxlumo can significantly reduce the levels of oxalate in the body in patients with primary hyperoxaluria type 1. Although the number of patients recruited was small due to the rarity of the disease, the effectiveness of the medicine was shown consistently across all age groups. The side effects of Oxlumo are mild or moderate. The European Medicines Agency therefore decided that Oxlumo's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Oxlumo?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Oxlumo have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Oxlumo are continuously monitored. Side effects reported with Oxlumo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Oxlumo

Oxlumo received a marketing authorisation valid throughout the EU on 19 November 2020.

Oxlumo : EPAR - Medicine overview

Adopted

Reference Number: EMA/561348/2020

English (EN) (102.36 KB - PDF)

**First published:** 25/11/2020

[View](/en/documents/overview/oxlumo-epar-medicine-overview_en.pdf)

Oxlumo : EPAR - Risk-management-plan summary

English (EN) (261.52 KB - PDF)

**First published:** 25/11/2020

**Last updated:** 13/10/2022

[View](/en/documents/rmp-summary/oxlumo-epar-risk-management-plan-summary_en.pdf)

## Product information

Oxlumo : EPAR - Product information

English (EN) (522.08 KB - PDF)

**First published:** 25/11/2020

**Last updated:** 13/10/2025

[View](/en/documents/product-information/oxlumo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-547)

български (BG) (634.17 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/bg/documents/product-information/oxlumo-epar-product-information_bg.pdf)

español (ES) (524.25 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/es/documents/product-information/oxlumo-epar-product-information_es.pdf)

čeština (CS) (583.13 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/cs/documents/product-information/oxlumo-epar-product-information_cs.pdf)

dansk (DA) (555.26 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/da/documents/product-information/oxlumo-epar-product-information_da.pdf)

Deutsch (DE) (661.15 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/de/documents/product-information/oxlumo-epar-product-information_de.pdf)

eesti keel (ET) (520.53 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/et/documents/product-information/oxlumo-epar-product-information_et.pdf)

ελληνικά (EL) (691.34 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/el/documents/product-information/oxlumo-epar-product-information_el.pdf)

français (FR) (579.5 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/fr/documents/product-information/oxlumo-epar-product-information_fr.pdf)

hrvatski (HR) (579.52 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/hr/documents/product-information/oxlumo-epar-product-information_hr.pdf)

íslenska (IS) (530.42 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/is/documents/product-information/oxlumo-epar-product-information_is.pdf)

italiano (IT) (556.96 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/it/documents/product-information/oxlumo-epar-product-information_it.pdf)

latviešu valoda (LV) (689.44 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/lv/documents/product-information/oxlumo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (636.54 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/lt/documents/product-information/oxlumo-epar-product-information_lt.pdf)

magyar (HU) (693.55 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/hu/documents/product-information/oxlumo-epar-product-information_hu.pdf)

Malti (MT) (728.14 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/mt/documents/product-information/oxlumo-epar-product-information_mt.pdf)

Nederlands (NL) (565.04 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/nl/documents/product-information/oxlumo-epar-product-information_nl.pdf)

norsk (NO) (616.86 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/no/documents/product-information/oxlumo-epar-product-information_no.pdf)

polski (PL) (623.14 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/pl/documents/product-information/oxlumo-epar-product-information_pl.pdf)

português (PT) (637.92 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/pt/documents/product-information/oxlumo-epar-product-information_pt.pdf)

română (RO) (670.43 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/ro/documents/product-information/oxlumo-epar-product-information_ro.pdf)

slovenčina (SK) (656.9 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/sk/documents/product-information/oxlumo-epar-product-information_sk.pdf)

slovenščina (SL) (595.74 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/sl/documents/product-information/oxlumo-epar-product-information_sl.pdf)

Suomi (FI) (512.1 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/fi/documents/product-information/oxlumo-epar-product-information_fi.pdf)

svenska (SV) (542.17 KB - PDF)

**First published:**

25/11/2020

**Last updated:**

13/10/2025

[View](/sv/documents/product-information/oxlumo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0000245133 04/08/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Oxlumo : EPAR - All authorised presentations

English (EN) (46.21 KB - PDF)

**First published:** 25/11/2020

[View](/en/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-916)

български (BG) (62.35 KB - PDF)

**First published:**

25/11/2020

[View](/bg/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_bg.pdf)

español (ES) (46.05 KB - PDF)

**First published:**

25/11/2020

[View](/es/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (61.47 KB - PDF)

**First published:**

25/11/2020

[View](/cs/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (47.9 KB - PDF)

**First published:**

25/11/2020

[View](/da/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (48.1 KB - PDF)

**First published:**

25/11/2020

[View](/de/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (45.35 KB - PDF)

**First published:**

25/11/2020

[View](/et/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (59.8 KB - PDF)

**First published:**

25/11/2020

[View](/el/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_el.pdf)

français (FR) (46.53 KB - PDF)

**First published:**

25/11/2020

[View](/fr/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (62.23 KB - PDF)

**First published:**

25/11/2020

[View](/hr/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (47.6 KB - PDF)

**First published:**

25/11/2020

[View](/is/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (45.48 KB - PDF)

**First published:**

25/11/2020

[View](/it/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (62.06 KB - PDF)

**First published:**

25/11/2020

[View](/lv/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (55.16 KB - PDF)

**First published:**

25/11/2020

[View](/lt/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (53.9 KB - PDF)

**First published:**

25/11/2020

[View](/hu/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (63.89 KB - PDF)

**First published:**

25/11/2020

[View](/mt/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (46.75 KB - PDF)

**First published:**

25/11/2020

[View](/nl/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (47.34 KB - PDF)

**First published:**

25/11/2020

[View](/no/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_no.pdf)

polski (PL) (65.32 KB - PDF)

**First published:**

25/11/2020

[View](/pl/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_pl.pdf)

português (PT) (48.03 KB - PDF)

**First published:**

25/11/2020

[View](/pt/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_pt.pdf)

română (RO) (61.08 KB - PDF)

**First published:**

25/11/2020

[View](/ro/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (61.68 KB - PDF)

**First published:**

25/11/2020

[View](/sk/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (54.32 KB - PDF)

**First published:**

25/11/2020

[View](/sl/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (42.88 KB - PDF)

**First published:**

25/11/2020

[View](/fi/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (46.15 KB - PDF)

**First published:**

25/11/2020

[View](/sv/documents/all-authorised-presentations/oxlumo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Oxlumo Active substance Lumasiran sodium International non-proprietary name (INN) or common name lumasiran Therapeutic area (MeSH) Hyperoxaluria, Primary Anatomical therapeutic chemical (ATC) code A16AX18

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Treatment of primary hyperoxaluria type 1 (PH1) in all age groups.

## Authorisation details

EMA product number EMEA/H/C/005040

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Alnylam Netherlands B.V.

Antonio Vivaldistraat 150

Opinion adopted 15/10/2020 Marketing authorisation issued 19/11/2020 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Oxlumo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (146.66 KB - PDF)

**First published:** 02/10/2025

[View](/en/documents/procedural-steps-after/oxlumo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Oxlumo : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (177.7 KB - PDF)

**First published:** 13/09/2021

**Last updated:** 02/10/2025

[View](/en/documents/procedural-steps-after/oxlumo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Oxlumo : EPAR - Public assessment report

Adopted

Reference Number: EMA/568312/2020

English (EN) (3.57 MB - PDF)

**First published:** 25/11/2020

[View](/en/documents/assessment-report/oxlumo-epar-public-assessment-report_en.pdf)

Oxlumo : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMA/OD/0000034914

English (EN) (251.25 KB - PDF)

**First published:** 25/11/2020

[View](/en/documents/orphan-maintenance-report/oxlumo-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

CHMP summary of positive opinion for Oxlumo

Adopted

Reference Number: EMA/CHMP/529305/2020

English (EN) (132.62 KB - PDF)

**First published:** 16/10/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-oxlumo_en.pdf)

#### News on Oxlumo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020) 16/10/2020

[First treatment for rare condition primary hyperoxaluria type 1](/en/news/first-treatment-rare-condition-primary-hyperoxaluria-type-1) 16/10/2020

#### More information on Oxlumo

- [EU/3/16/1637 - orphan designation for treatment of primary hyperoxaluria](/en/medicines/human/orphan-designations/eu-3-16-1637)
- [BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1) - post-authorisation study](https://catalogues.ema.europa.eu/study/44283)

**This page was last updated on** 13/10/2025

## Share this page

[Back to top](#main-content)